ACOR — Acorda Therapeutics Share Price
Last Trade - 00:00- $34.16m
- $154.29m
- $153.73m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 519.6 | 588.29 | 471.43 | 192.41 | 152.97 | 120.38 | 120.52 | -20.86% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.
Directors
- John Kelley NEC (67)
- Ron Cohen (65)
- Robert Morales CFO (54)
- Burkhard Blank OTH (66)
- Lauren Sabella OTH (60)
- Peder Jensen (66)
- Sandra Panem (74)
- Lorin Randall (77)
- Last Annual
- December 31st, 2020
- Last Interim
- March 31st, 2021
- Incorporated
- March 17th, 1995
- Public Since
- February 10th, 2006
- No. of Shareholders
- 16
- No. of Employees
- 167
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 9,488,596
- Address
- 420 Saw Mill River Rd, ARDSLEY, 10502-2605
- Web
- http://www.acorda.com
- Phone
- +1 9143474300
- Auditors
- Ernst & Young LLP
Latest News for ACOR
Upcoming events for ACOR
Q3 2021 Acorda Therapeutics Inc Earnings Release
Similar to ACOR
ADAPTIMMUNE THERAPEUTI ADR REP 6 ORD
NASDAQ Global Select Market
AGIOS PHARMACEUTICALS ORD
NASDAQ Global Select Market
AKERO THERAPEUTICS ORD
NASDAQ Global Select Market
AKOUOS ORD
NASDAQ Global Select Market
ALECTOR ORD
NASDAQ Global Select Market
FAQ
As of Today at 13:32 UTC, shares in Acorda Therapeutics are trading at $3.60. This share price information is delayed by 15 minutes.
Shares in Acorda Therapeutics last closed at $3.60 and the price had moved by -5.35% over the past 365 days. In terms of relative price strength the Acorda Therapeutics share price has underperformed the S&P500 Index by -28.19% over the past year.
The overall consensus recommendation for Acorda Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Acorda Therapeutics does not currently pay a dividend.
Acorda Therapeutics does not currently pay a dividend.
Acorda Therapeutics does not currently pay a dividend.
To buy shares in Acorda Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $3.60, shares in Acorda Therapeutics had a market capitalisation of $34.16m.
Here are the trading details for Acorda Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ACOR
Shares are classified based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Acorda Therapeutics does not currently have a style classification.
The analyst consensus target price for shares in Acorda Therapeutics is $10.00. That is 177.78% above the last closing price of $3.60.
Analysts covering Acorda Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$7.64 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Acorda Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -54.25%.
As of the last closing price of $3.60, shares in Acorda Therapeutics were trading -26.56% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Acorda Therapeutics.
Acorda Therapeutics' management team is headed by:
- John Kelley - NEC
- Ron Cohen -
- Robert Morales - CFO
- Burkhard Blank - OTH
- Lauren Sabella - OTH
- Peder Jensen -
- Sandra Panem -
- Lorin Randall -
We do not have data on Acorda Therapeutics' shareholders